SS Innovations International

SS Innovations International

SS Innovations was founded by Dr. Sudhir Srivastava after a career that included performing the first robotic cardiac surgery in Asia. The firm is structured as a commercial entity rather than a family office, dedicating its operations entirely to the design, regulatory approval, and commercialization of the SSI Mantra surgical robotic system, which received Indian regulatory approval in 2022. The firm's mission is predicated on a cost-arbitrage thesis where the capital cost of its system is targeted at roughly one-third of the incumbent standard. The firm's strategy centers on manufacturing the multi-arm SSI Mantra system in India. The device is designed for a broad range of minimally invasive procedures including cardiac, urological, gynecological, and general surgeries. Deployment has focused initially on the domestic Indian market as a category-creator at a lower price tier, alongside early international pilots in regions seeking affordable robotic surgery alternatives. Known installations include public and private hospital sites across India, with clinical data being presented at medical congresses to support broader adoption. Dr. Srivastava leads the organization as Chairman and CEO, operating from the firm's headquarters in Gurugram. The company operates a manufacturing and training facility in India. It is publicly traded on the OTC market in the United States, a corporate structure that reflects its capital-raising pathway to scale manufacturing. The firm has pursued direct sales, placement agreements, and leasing models to lower the barrier to entry for hospitals adopting robotic platforms for the first time. SS Innovations' structural differentiator is its vertical integration in a market defined by extreme capital concentration. By manufacturing in India and targeting a price point that competes with open-surgery consumable costs rather than Western robotic capital budgets, the firm is attempting to force the diffusion curve for surgical robotics in underserved global markets — a strategy that pits it directly against the capital intensity of the dominant, incumbent competitor.